Mersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares stood at 3.48 million during the last session, with the company’s beta value hitting 1.54. At the close of trading, the stock’s price was $0.46, to imply a decrease of -2.15% or -$0.01 in intraday trading. The MRSN share’s 52-week high remains $5.11, putting it -1010.87% down since that peak but still an impressive 4.35% since price per share fell to its 52-week low of $0.44. The company has a valuation of $57.20M, with an average of 2.67 million shares in intraday trading volume over the past 10 days and average of 5.66 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Mersana Therapeutics Inc (MRSN), translating to a mean rating of 1.40. Of 5 analyst(s) looking at the stock, 0 analyst(s) give MRSN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
After registering a -2.15% downside in the last session, Mersana Therapeutics Inc (MRSN) has traded red over the past five days. The 5-day price performance for the stock is -10.05%, and -21.24% over 30 days. With these gigs, the year-to-date price performance is -67.90%. Short interest in Mersana Therapeutics Inc (NASDAQ:MRSN) saw shorts transact 10.32 million shares and set a 2.26 days time to cover.
The extremes give us $3 and $3 for target low and target high price respectively. As such, MRSN has been trading -552.17% off suggested target high and -552.17% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 2.74% for the past 5-year period. While 2025 is set for a -28.16% return in earnings, projections for the next 5 years are at -13.09% annually.
MRSN Dividends
Mersana Therapeutics Inc has its next earnings report out on 2025-Mar-02. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
Mersana Therapeutics Inc insiders hold 1.40% of total outstanding shares, with institutional holders owning 85.51% of the shares at 86.72% float percentage. In total, 85.51% institutions holds shares in the company, led by ECOR1 CAPITAL, LLC. As of 2024-06-30, the company held over 19.36 million shares (or 15.8156% of shares), all amounting to roughly $38.92 million.
The next major institution holding the largest number of shares is VR ADVISER, LLC with 11.33 million shares, or about 9.2519% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.77 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Mersana Therapeutics Inc (MRSN) shares. Going by data provided on Dec 31, 2024, Vanguard Total Stock Market Index Fund holds roughly 3.47 shares. This is just over 2.78% of the total shares, with a market valuation of $1.59 million. Data from the same date shows that the other fund manager holds a little less at 3.11, or 2.50% of the shares, all valued at about 1.43 million.
